Management EfficiencyThe company has return on total asset (ROA) of (54.71) % which means that it has lost $54.71 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (117.11) % meaning that it generated substantial loss on money invested by shareholders.
Entity SummaryBiotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus. Biotron operates under Biotechnology classification in USA and traded on OTC Market. It employs 3 people.Biotron Limited (BITRF) is traded on OTC Market in USA. It is located in 56 Delhi Road and employs 3 people.
Biotron Limited Leadership Team
Stock Performance Indicators